CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Tuesday

CRISPR Therapeutics (NASDAQ:CRSP) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($1.32) per share and revenue of $8.7390 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 12:00 AM ET.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.18. The business had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The company’s revenue for the quarter was up 72.5% on a year-over-year basis. During the same period in the previous year, the company earned ($1.49) EPS. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $63.99 on Friday. The firm has a market capitalization of $5.82 billion, a PE ratio of -11.78 and a beta of 1.84. The business’s fifty day moving average price is $62.53 and its 200 day moving average price is $52.44. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $78.48.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction on Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at $17,262,789.91. The trade was a 16.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel James R. Kasinger sold 1,076 shares of the company’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the sale, the general counsel owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 56,213 shares of company stock valued at $3,810,458. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cerity Partners LLC raised its holdings in shares of CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after buying an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp grew its holdings in shares of CRISPR Therapeutics by 3.0% during the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after buying an additional 200 shares during the last quarter. Strategic Wealth Investment Group LLC acquired a new position in CRISPR Therapeutics in the 2nd quarter valued at about $36,000. BNP Paribas Financial Markets raised its stake in CRISPR Therapeutics by 4.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 19,257 shares of the company’s stock valued at $937,000 after acquiring an additional 842 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in CRISPR Therapeutics by 538.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,800 shares of the company’s stock valued at $88,000 after acquiring an additional 1,518 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRSP has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $81.00 price objective on shares of CRISPR Therapeutics in a report on Friday, October 10th. Barclays boosted their target price on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Royal Bank Of Canada increased their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a research note on Tuesday, August 5th. Chardan Capital reissued a “buy” rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. Ten analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $72.59.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.